### Amphotericin B

**Indication**: Histoplasmosis  
**ICD11 code**: 1F68.Z

**INN**: Amphotericin B

**Medicine type**: Chemical agent

**List type**: Core

**Formulations**: Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex); 50 mg in vial powder for injection (as sodium deoxycholate)

**EML status history**
- First added in 1977 (TRS 615)
- Changed in 1979 (TRS 641)
- Changed in 1984 (TRS 722)
- Changed in 2003 (TRS 920)
- Changed in 2007 (TRS 950)
- Changed in 2009 (TRS 958)
- Changed in 2013 (TRS 985)
- Changed in 2023 (TRS 1049)

**Sex**: All

**Age**: Also recommended for children

**Therapeutic alternatives**: The recommendation is for this specific medicine

**Patent information**: Patents have expired in most jurisdictions  
Read more about patents.

**Wikipedia**: [Amphotericin B](https://en.wikipedia.org/wiki/Amphotericin_B)

**DrugBank**: [Amphotericin B](https://www.drugbank.ca/drugs/DB00544)

---

**Summary of evidence and Expert Committee recommendations**

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the listing for amphotericin B on the EML and EMLc be amended to list the liposomal and deoxycholate formulations separately, and the inclusion of a note to indicate that liposomal amphotericin B is the preferred formulation because of its better safety profile.